Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nevis Brands Inc C.NEVI

Alternate Symbol(s):  NEVIF

Nevis Brands Inc., formerly Pascal Biosciences Inc., provides cannabis brands throughout the United States. The Company provides products in Washington, Oregon, California, Ohio, Arizona and Colorado through partners and licensees. Its products include Major, which is a cannabis beverage. Major is a high-dose tetrahydrocannabinol (THC) beverage that delivers a consistent cannabis experience with no cannabis taste or smell. Major offers various flavors, such as volcanic orange mango, sunset pink lemonade, pacific coast blue raspberry, dreamin' of passion, and sacred grape. It also offers Major Minis, which is a smaller 2 ounce (oz) shot. Major Minis comes in three flavors, such as blueberry, fruit punch, and blackberry lemonade.


CSE:NEVI - Post by User

Bullboard Posts
Post by good2004on Feb 23, 2018 12:32pm
64 Views
Post# 27610004

NEWS

NEWS
Pascal Biosciences arranges $5M private placement 2018-02-23 11:23 ET - News Release Dr. Patrick Gray reports PASCAL BIOSCIENCES INC. ANNOUNCES NON-BROKERED PRIVATE PLACEMENT Pascal Biosciences Inc. has arranged a non-brokered private placement of up to 12.5 million units at a price of 40 cents per unit for gross proceeds of up to $5-million. Each unit will consist of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the company at a price of 60 cents per share for a period of 12 months from the date of closing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the company may exercise once the units are free of resale restrictions and if the company's shares are trading at or above a volume weighted average price of 80 cents for 10 consecutive trading days, the warrants will expire upon 30 days from the date the company provides notice in writing to the warrant holders via a news release. The proceeds from the sale of units will be added to working capital in furtherance of the company's business. The securities to be issued under the placement will be subject to a four-month hold period and the private placement is subject to the acceptance of the TSX Venture Exchange. About Pascal Biosciences Inc. Pascal Biosciences is a drug discovery and development company focused on harnessing the body's immune system to fight cancer. The company's three significant technologies are: 1. Utilizing proprietary screening systems for identifying novel compounds that are able to restore immune recognition and killing of cancer cells; 2. Exploiting the regulation of specific calcium channels expressed by cells of the immune system. By regulating these calcium channels, immune activity can be controlled to combat cancers, infections and autoimmune diseases; 3. Developing a therapeutic monoclonal antibody for B-cell precursor acute lymphoblastic leukemia, the most common childhood leukemia, in collaboration with the University of New Mexico.
Bullboard Posts